STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
An experimental Alzheimer's drug from Biogen, one with a novel approach, slowed decline at comparable rates as approved drugs in a mid-stage study.
Read the full articleYou might also wanna read
New experimental Alzheimer’s drug shows potential after study shows slower cognitive decline
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers found.
AAIC: Biogen bolsters hopes for Alzheimer's pivotal push as anti-tau oligo slows cognitive decline
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharm
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
An experimental Alzheimer’s drug shows promise targeting a different brain protein, new study shows
The company Biogen is planning a larger study to try to prove the drug’s benefit.
Comments
Sign in to join the conversation.
No comments yet. Be the first.